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Safety switches are becoming relevant for the clinical 
translation of T-cell–based immunotherapies. In patients 
receiving an allogeneic hematopoietic stem cell trans-
plant, the inducible caspase-9 gene (iC9) safety switch 
expressed by donor-derived T lymphocytes efficiently 
controls acute graft versus host disease (GvHD). How-
ever, in vivo elimination of iC9-T cells by the chemical 
inducer of dimerization (CID) that activates the iC9 pro-
tein is incomplete. To study this effect, we characterized 
the clonal diversity and dynamics of vector insertion sites 
(VIS) in iC9-T cells pre- and post-CID administration in 
four patients who developed GvHD. We identified 3,203 
VIS among four patients and followed their in vivo clonal 
dynamics up to 161 days post-CID. VIS were catego-
rized by their proximity to host genome elements, gene 
associations, and cis-modulatory relationship to mapped 
promoters. We found that VIS are preferentially located 
near open chromatin and promoter regions; further-
more, there was no evidence for selection bias among 
VIS surviving the CID treatment. The majority of iC9-T 
cells with high normalized VIS copy number at the time 
of GvHD onset were eliminated by CID, while iC9-T cells 
detectable post-CID generally have low normalized VIS 
copy number. We propose that suboptimal iC9  transgene 
expression is responsible for the incomplete elimination 
of iC9-T cells and illustrate here by simple model how 
cis-modulatory influences of local genome context and 
T-cell receptor activation status at time of CID treatment 
contribute to stochastic sparing of iC9-T cells.
Received 1 June 2015; accepted 23 November 2015; advance online  
publication 5 January 2016. doi:10.1038/mt.2015.217
INTRODUCTION
The infusion of donor-derived T lymphocytes engineered to 
express the herpes simplex virus thymidine kinase (HSV-TK) 
safety switch allows efficient control of acute graft versus host dis-
ease (GvHD) in patients receiving allogeneic hematopoietic stem 
cell transplant (HSCT).1 We recently demonstrated that another 
safety switch based on the inducible caspase-9 gene (iC9) achieves 
the same clinical benefits.2,3
Extending from their original application to control GvHD, 
safety switches are increasingly relevant for the clinical transla-
tion of other T-cell–based immunotherapies. For example, safety 
switches may be desirable to control the life-threatening toxicities 
caused by T lymphocytes engineered to acquire antitumor speci-
ficity, such as T lymphocytes expressing chimeric antigen recep-
tors or T-cell receptors (TCRs).4–6 For these applications, the iC9 
safety switch is potentially superior to HSV-TK as it is less immu-
nogenic,7,8 induces apoptosis of engineered cells within hours 
in vivo,9 and is functional in both dividing and nondividing cells 
since it directly activates apoptosis independently of cell cycle.7–10
Clinical experience thus far indicates >90% elimination of 
iC9-T cells infused after HSCT within few hours of administration 
of the chemical inducer of dimerization (CID) AP1903, which 
activates the fusion protein iC9. There remains, however, a frac-
tion of iC9-T cells that are not eliminated in vivo.2,3 These iC9-T 
cells are not intrinsically resistant to apoptosis, since they can be 
eliminated ex vivo in response to CID after re-activation.2 While 
incomplete elimination of iC9-T cells in vivo by CID has not pro-
duced adverse clinical consequences after allogeneic HSCT, since 
GvHD is permanently controlled,2,3 it is still critical to dissect the 
mechanisms responsible for the incomplete in vivo elimination of 
iC9-T cells by CID.
Earlier studies of T cells engineered with HSV-TK elucidated 
that Moloney murine leukemia retrovirus integration preferen-
tially occurs near active promoters and regulatory elements, as was 
previously observed for hematopoietic stem cells.11–13 We hypoth-
esized that murine leukemia retrovirus integration in those iC9-T 
lymphocytes not eliminated in vivo by CID may be located in 
transcriptionally inactive chromatin regions, which downregulate 
transgene expression. To investigate this possibility, we performed 
high-resolution mapping of gammaretroviral vector integration 
sites (GRV VIS) from samples taken from patients who devel-
oped GvHD after the infusion of iC9-T cells2,3 and assessed total 
VIS diversity per patient up to 161 days post-CID. We then used 
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published genome-wide atlases to dissect genomic and epigenetic 
influences on the clonal dynamics of T cells expressing the iC9 
safety switch.
RESULTS
Proviral integrants in iC9-T cells are located near 
open chromatin and promoter regions
For all GRV VIS, we retained only uniquely mapped reads within 
100 bp of VIS as the modified sequencing read depth (Truncated 
Read Coverage). Overall, from the 12 samples collected, we recov-
ered a total of 650, 748, 1,079, and 726 unique VIS from Pts. 1, 
2, 4, and 5, respectively2,3 (Table  1). We mapped genomic dis-
tances between VIS and four commonly referenced functional 
elements such as RefSeq transcriptional start sites (TSS), DNase 
I-hypersensitive sites (DHS), CpG islands (CGI), and hypometh-
ylated regions (HMR). For comparison and benchmarking, we 
included two previously published studies analyzing VIS in T cells 
transduced with a GRV-encoding HSV-TK13 and a study in which 
human T lymphocytes were infected in vitro with HIV.14 Our own 
and previous analyses11,13 revealed site selection bias for GRV that 
is distinct from lentivirus. GRV preferentially integrate near func-
tional elements closely associated with transcriptional activity 
such as TSS and CpG islands, and about 40% of GRV VIS were 
found within ±5 kb of TSS compared to ~15% for HIV (Figure 1). 
Greater than 25% of GRV VIS mapped within 2 kb distance of 
CpG islands, termed “CpG shores.” In contrast, only 7% of lentivi-
rus integrants were found at distances of <2 kb. DHS indicate rela-
tive “open” chromatin accessibility for DNA-binding factors, and 
we found ~70% GRV VIS in or very near DHS (±1 kb distance), 
compared to ~35% for lentiviral integrants (Figure  1). When 
we examined VIS relative to HMR mapped in peripheral blood 
mononuclear cells, 40–60% of all GRV VIS were found within 1 kb 
distance of HMR, in contrast to <5% for lentiviral integrants.
Mapping of integration sites within chromatin states
We next characterized the genomic regions near VIS, by mapping 
VIS to chromatin state annotation specific to CD4+ memory T-cell 
genome by the ChromHMM algorithm, which has been used to 
discover gene regulatory regions.15 The 51 discrete chromatin states 
can be broadly categorized under five major categories: Promoter 
(states 1–11), Transcribed (states 12–28), Active Intergenic (states 
29–39), Repressive (states 40–45), and Repetitive (states 46–51). 
From the 3,203 VIS recovered from four patients, 3,168 were cat-
egorized based on the chromatin state distribution as: 720 (22.4%) 
Promoter, 674 (20.7%) Transcribed, 1,466 (46%) Active Intergenic, 
283 (9%) Repressive, and 25 (0.8%) Repetitive (Figure 2a,b). We 
repeated similar mapping analyses for published VIS sets for GRV 
and lentivirus13,14 (Figure 2c). T-cell transduction by either class 
of vectors leads to integration patterns that are skewed towards 
chromatin states associated with open and transcriptionally 
active regions (Promoter, Transcribed, Active Intergenic states), 
whilst avoiding Repressive and Repetitive states (Figure  2c and 
Supplementary Figure S1). However, the relative enrichment in 
Transcribed and Active Intergenic states discriminates between 
GRV VIS (favoring Active Intergenic states 29–33) from lentiviral 
integration (favoring Transcribed states 22–28). Although GRV 
VIS avoid Repetitive states, we observed they associate with Alu 
repeat elements. Indeed 1,052 VIS (30%) were located in states 16, 
19, 23, 26, 34, 36, and 37.
Genomic Regions Enrichment of Annotations Tool 
analysis
Having found that VIS are preferentially located within regions 
functionally enriched for transcriptional regulation, we then 
assessed their association with gene programs using GREAT 
(Genomic Regions Enrichment of Annotations Tool) analysis.16 
The 3,203 identified VIS were significantly enriched in Gene 
Ontology (GO) Biological Processes relating to immune cell func-
tion, T-cell costimulation, Type I interferon response, NF-κB 
cascade, and Toll-like receptor 3 signaling pathway (Figure 2a). 
These GO Biological Processes reflect gene functions typical of T 
cells, which are likely to be transcriptionally active in proliferat-
ing T cells at the time of GRV transduction. In contrast, lentiviral 
integrants are enriched for cell cycle regulation and DNA integrity 
checkpoints (Supplementary Figure S1). For immunity-related 
GO Biological Processes shared by both GRV and lentiviral 
Table 1 Summary of peripheral blood samples from patients infused with iC9-T cells who developed GvHD
Pt.#
Time of collection 
post-CID (days)
iC9 copies/µg DNA  
by qPCR on total PBMC
Unique sequence 
reads on total PBMC
CD3+ CD9+ 
(cells/µl)
CD3+ CD9+ 
CD4+ (cells/µl)
CD3+ CD9+ 
CD8+ (cells/µl)
#1 −1 174,389 456,510 348 340 8
13 50,551 271,380 130 115 6
79 29,099 463,351 44 14 28
#2 0 87,174 1,314,865 236 100 133
14 5,515 922,093 11 4 5
161 9,430 145,010 64 13 46
#4 −3 71,823 1,034,558 118 10 108
32 5,707 516,794 35 2 32
74 5,988 457,993 75 6 73
#5 0 45,751 194,009 151 98 45
2 2,735 1,315,633 6 2 3
94 2,841 1,008,959 37 3 32
CID, chemical inducer of dimerization; GvHD, graft versus host disease; PBMC, peripheral blood mononuclear cell; qPCR, quantitative PCR.
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integrants (T-cell costimulation, GO:0031295; Induction of apop-
tosis, GO:0006917), GREAT showed preferential integration of 
GRV versus lentivirus (Figure 2a and Supplementary Figure S1). 
Thus VIS patterning as annotated by ChromHMM and GREAT 
gives insight into viral integration behavior and pinpoints cell 
differentiation status at time of viral integration into the host 
genome.
Effects of iC9 gene activation by CID on VIS diversity
Having functionally dissected VIS pattern in iC9-T cells in vivo, 
we assessed the impact of CID administration on the VIS clonal 
dynamics. To accurately estimate copy number of iC9 transgenes 
per VIS, we normalized total uniquely mapped sequencing reads 
per sequencing library against their respective iC9 transgene copy 
numbers measured by quantitative PCR to arrive at a normalized 
VIS copy number (NVC) for all VIS (Figure 3 and Supplementary 
Figures S2 and S3). Analyzed peripheral blood mononuclear cell 
samples were broadly categorized as pre-CID (day 0 prior to CID 
administration), post-CID (2–32 days post-CID administration), 
or late-CID (74–161 days post-CID administration), and VIS were 
segregated by using two criteria: (i) change of NVC levels and (ii) 
length of persistence in vivo. Using these two criteria, we identi-
fied four distinct groups: Sensitive/Eliminated,  Insensitive/Short-
term, Sensitive/Persisted, and Insensitive/Persisted (Figure 3 and 
Supplementary Figure S2). In all patients except Pt. 1, majority 
of VIS (75–87%) were grouped as Sensitive/Eliminated if NVC 
levels decreased in pre-CID to post-CID samples then fell below 
our present detection threshold (i.e., 1 NVC copy; see Materials 
and Methods) in late-CID samples (Figure 3 and Supplementary 
Figure S2). In addition, we identified three other patterns of 
VIS clonal dynamic. VIS were defined Insensitive/Short-term 
when NVC increased from pre-CID to post-CID samples but 
became undetectable in late-CID samples. VIS were categorized 
as Sensitive/Persisted if NVC dropped from pre-CID to post-CID 
samples but remained detectable in late-CID samples. Finally, 
the last group of VIS we termed Insensitive/Persisted because 
NVC increased from pre-CID to post-CID samples and then 
remained consistently detectable in late-CID samples (Figure  3 
and Supplementary Figure S2). With the exception of Pt.1, VIS 
with highest NVC at the time of GvHD occurrence (pre-CID) 
disappeared in post-CID and late-CID samples, while a minority 
persisted in late-CID samples (11.3, 25.5, and 15.8% for Pts. 2, 4, 
Figure 1 Distribution of VIS by chromosome and mapped distance to functional DNA elements. (a) Chromosomal distribution of VIS detected in 
four patients. (b) Mapped distance distribution of VIS to nearest RefSeq TSS binned at 5 kb distance intervals centered about TSS. Negative distances 
denotes upstream of TSS. (c) Mapped distance distribution of VIS to nearest CpG island (UCSC). VIS mapped to nearest CpG island are annotated 
as “island” (zero distance), “shore” (up to 2 kb), “2–5 kb” then set at 5 kb distances intervals up to 50 kb. (d) Mapped distance distribution of VIS 
to nearest DNaseI-hypersensitive site in CD3+ T-cell genome (Epigenetic Roadmap Project EID: E034; narrowPeak). VIS at zero distance (“on”) and 
then set at 1 kb distance intervals up to 10 kb. (e) Mapped distance distribution of VIS to nearest hypomethylated region in human peripheral blood 
mononuclear cell genome (ENCODE dataset36). VIS at zero distance (“on”) and then set at 1 kb distance intervals up to 10 kb. (b–e) Percent of total 
VIS found per experiment dataset (CASP, this study; Cattoglio = Cattoglio et al.13; Sherrill-Mix = Sherrill-Mix et al.14). TSS, transcriptional start site; 
VIS, vector integration sites.
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and 5, respectively). Of note, VIS predominant in late-CID samples 
initially showed low NVC levels in pre-CID samples (Figure 3 and 
Supplementary Figure S2). When VIS diversity is viewed by its 
cognate ChromHMM states, we did not observe clonal selection 
by CID treatment (Supplementary Figure S4). Instead these data 
indicate CID sensitivity tracks closely with the clonal expansion of 
iC9-T cell subsets at time of GvHD onset, suggesting that expand-
ing iC9-T cells are alloreactive and have activated TCR signaling. 
By contrast, VIS species with initially low pre-CID NVC levels 
may represent iC9-T cells quiescent at time of GvHD onset with 
Figure 2 Functional annotation and gene ontology enrichment of VIS. (a) Representative list of GO Biological Process terms significantly enriched 
for 3,203 gammaretroviral VIS in this study. Gene ontology enrichment is computed by binomial testing implemented by Genomic Regions Enrichment 
of Annotations Tool (GREAT). Select results shown for binomial test rank, Bonferroni-adjusted, and unadjusted P values are shown. (b) Matrix 
table showing number of VIS shared between ChromHMM-defined states (rows) and select GO Biological Process terms (columns). ChromHMM 
states are broadly grouped as: Promoter (states 1–11), Transcribed (12–28), Active Intergenic (29–39), Repressive (40–45), and Repetitive (46–51). 
(c) Frequency distribution of ChromHMM states per patient (Pt. 1–5; this study); Cattoglio (retroviral vector study)13; Sherrill-Mix (lentiviral in vitro)14; 
and Random. TSS, transcriptional start site; VIS, vector integration sites.
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35 21 6 8 5 9 6 4 10 4 3 19 3 3 23 2 2 0 3 1 4 0 35 0 12 2 2 6 60 35 Active intergenic regions not enhancer specific
36 72 29 32 27 39 24 26 19 7 15 49 21 21 72 16 14 8 11 5 14 6 83 4 37 10 8 29 192 36 Active intergenic further from enhancers; Alu repeats
37 60 14 19 15 36 16 22 18 4 8 41 10 15 79 9 5 6 2 1 5 1 91 1 28 3 4 16 261 37 Non-repressive intergenic domains; Alu repeats
38 21 5 6 6 14 2 5 4 0 3 14 6 4 25 2 4 2 2 2 0 0 32 1 9 4 1 12 100 38 H2AZ specific state
39 2 0 0 0 2 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 1 0 2 1 5 39 CTCF island; candidate insulator
40 13 0 1 1 6 2 5 4 0 5 13 0 5 16 1 0 1 1 0 0 0 11 0 4 0 1 5 81 40 Unmappable
41 5 1 1 1 4 0 1 3 0 2 12 0 2 13 0 0 0 0 0 1 0 17 0 8 1 0 5 58 41 Heterochr; nuclear lamina; most AT rich
42 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 42 Heterochr; nuclear lamina; ERVL repeats
43 16 7 6 5 17 5 9 4 3 2 19 3 4 42 1 1 1 1 0 2 1 54 0 11 0 1 10 137 43 Heterochr; lower gene depletion
44 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 44 Heterochr; ERVL repeats: lower gene/exon depletion
45 2 1 1 0 2 0 1 0 0 0 1 1 1 3 0 0 0 0 0 1 1 0 0 0 1 0 2 5 45 Specific repression
46 2 0 0 0 2 0 0 0 0 0 1 0 0 2 0 0 0 0 0 0 0 4 0 1 0 0 1 12 46 Simple repeats (CA)n, (TG)n
47 3 0 1 1 1 0 1 1 0 0 2 0 0 2 0 0 0 0 0 0 0 4 0 2 0 0 0 6 47 L1/LTR repeats
48 1 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 6 0 0 0 0 1 5 48 Satellite repeat
49 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 49 Satellite repeat; moderate mapping bias
50 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 50 Satellite repeat; high mapping bias
51 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 2 51 Satellite repeat/rRNA; extreme mapping bias
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consequent low expression of the iC9 transgene. To experimen-
tally validate this hypothesis, we performed in vitro experiments 
with iC9-T cells generated for clinical use, sorted into CD19Lo and 
CD19Hi populations by surface CD19 expression (Supplementary 
Figure S4). We quantitated iC9 transgene expression (mRNA) 
by quantitative PCR while controlling for proviral insertion copy 
numbers (genomic DNA) in either steady state condition or fol-
lowing activation with CD28/OKT3 mAbs. As expected, iC9 trans-
gene expression is functionally tied to proviral integration copies 
and mirrors surface CD19 expression. By quantitative PCR quan-
titation, iC9 transgene level in activated CD19Lo cells surpassed 
steady state CD19Hi cells. Furthermore, fold increase of iC9 trans-
gene expression was greater in CD19Lo versus CD19Hi cells upon 
activation with CD28/OKT3 mAbs (Supplementary Figure S4).
Epigenetic changes and transcriptional regulation of 
nearby host promoters
We next examined the epigenetic features proximal to the VIS 
and functional properties of nearby host promoter/enhancers that 
may also affect the iC9 transgene expression and consequent sen-
sitivity to CID treatment.
Methylation profile of VIS-flanking CpG dinucleotides. We 
investigated the influence of peripheral CpG methylation on 
transgene expression by querying the methylation status, CpG 
ratio, and GC content of VIS-flanking sequences using meth-
ylCRF estimates for CD4+ memory T cells.17,18 In general, we 
observed low GC frequency and concomitantly high methyla-
tion for VIS-adjacent sequences (Figure 4). Of the 3,203 VIS-
adjacent regions, 2,687 (83.9%), 450 (14.0%), and 53 (1.6%) 
were categorized as low CpG promoters (LCP), intermediate 
CpG promoters (ICP), or high CpG promoters (HCP), respec-
tively, while four VIS-adjacent regions were not categorized. 
Overall, the methylation profile distribution for GRV VIS is 
skewed toward low CpG density with high methylation, where-
as RefSeq TSS are typically of high CpG density at low methyla-
tion.18 No clear association of VIS sensitivity was observed to 
CID treatment.
Figure 3 Chemical inducer of dimerization (CID) response profiles of unique vector integration sites (VIS). For each gamma retroviral VIS, 
we estimate VIS copy number by tallying only sequencing read counts found within +100 bp of VIS, normalized by overall quantitative PCR trans-
gene copy number per peripheral blood mononuclear cell sample. Time-scale plot of normalized VIS copy number for (a) Pt. 1, (b) Pt. 2, (c) Pt. 4, 
(d) Pt. 5. VIS present only before CID (pre-CID) were defined as “Eliminated” while VIS present at the last time point (i.e., late-CID) were considered 
“Persisted,” remaining VIS were termed “Short-term.” We also considered whether copy number change pre- versus post-CID infusion was either 
negative or positive (“Sensitive” versus “Insensitive”) to CID induction, respectively. Using these criteria, we segregated recovered VIS into four broad 
CID profiles (“Sensitive/Eliminated,” “Insensitive/Short-term,” “Sensitive/Persisted,” and “Insensitive/Persisted”).
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DNase-hypersensitive sites near VIS. We examined the spac-
ing and density of open chromatin near the VIS using DNase-seq 
dataset for primary CD4+ memory T cells.19–22 For each VIS, we 
surveyed ±10 kb of the flanking region for sequencing coverage at 
10 bp smoothing resolution (Figure 5) according to the response 
to CID as described in Figure 3. We observed a distinctive dou-
ble peak around the VIS, which was clean and evenly spaced for 
VIS categorized as Sensitive/Eliminated. However, the pattern is 
devolved for the other three groups: Insensitive/Short-term per-
sisted, Sensitive/Persisted, and Insensitive/Persisted in relation to 
CID response. In these three groups, coverage pattern are often 
multipeaked with far larger amplitudes than the central VIS peak 
(Figure 5), suggesting dynamic local chromatin flux potentially 
influencing long terminal repeat (LTR) activity.
Transcriptional interference due to the orientation of VIS. 
We investigated whether the proximity and functional proper-
ties of nearby host promoter/enhancers could cross-modulate 
GRV LTR activity and cause transcriptional interference (TI). We 
used the recently released FANTOM5 CAGE dataset and identi-
fied individual CAGE peaks in CD4+ memory T cells (Haberle V: 
CAGEr: R package version 1.8.1.) and consolidated these peaks 
into “CAGE tag clusters” (CTSS).23 We categorized these de novo 
tandem configurations by the relative orientation of CTSS to VIS 
within ±1 kb distance as either: “divergent” when the CTSS is up-
stream and opposite VIS; “convergent” when the CTSS is down-
stream and reads into VIS; and “tandem” if the orientation of up/
downstream CTSS and VIS are the same. Approximately 49% 
(1,553 out of 3,203) of total VIS were located near at least one CTSS 
Figure 4 CpG methylation profile for vector integration sites (VIS) flanking regions. Scatter plots showing mean CpG dinucleotide methylation 
status (0.0–1.0; null to methylated) versus CpG ratio over ± 1 kb VIS-flanking region. Each point represents one VIS and is classified as low CpG pro-
moters (LCP: circle), intermediate CpG promoters (ICP: triangle), or high CpG promoters (HCP: square). Scatter plots are subcategorized according 
to chemical inducer of dimerization (CID) response profile (Sensitive/Eliminated, Insensitive/Short-term, Sensitive/Persisted, Insensitive/Persisted) and 
their pre-CID copy number levels.
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Figure 5 Distribution patterns of chromatin marks around vector integration sites (VIS). Sequencing coverage density of DNase-seq reads at 
VIS-flanking regions (±10 kb) smoothed at 10 bp resolution. Normalized density calculated as reads per million reads.
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at ±1 kb distance. Among these 1,553 VIS-proximal regions, we 
observed up to four interference configurations surrounding each 
VIS: divergent, convergent, upstream tandem, and downstream 
tandem (Figure 6a). We grouped VIS-associated regions by con-
figuration complexity (i.e., more than one de novo interference 
configurations) and categorized them according to both NVC 
levels at time of GvHD onset and response to CID (Figure 6b,c). 
VIS located among CTSS-dense regions ranked higher for com-
plexity. Approximately 22% (692) VIS are surrounded by one TI 
configuration and 16% (521), 7% (221), and 4% (133) have 2, 3, 
and 4 TI configurations, respectively (Figure 6b). We observed 
no correlation of interference configuration complexity with CID 
sensitivity.
TI and RNA polymerase II pausing. In addition to TI imparted 
by the orientation of the retroviral LTR insertion, mechanisms 
which govern RNPII (RNA polymerase II) initiation and elonga-
tion are likely also important.24–26 We surveyed RNPII ChIP-seq 
data from primary CD4+ T cells19 for both unphosphorylated (ini-
tiating; II0) and phospho-Ser5 (elongating; IIA) forms of RNPII 
at each CTSS. We systematically calculated “Stalling Index” de-
fined as enrichment of RNPII at CTSS (maximum read depth 
−300 to +600) versus median read depth spanning up to +10 kb 
downstream of the CTSS (modified from ref. 26). For this analy-
sis, we again categorized VIS by their CID sensitivity profile and 
compared the distributions of RNP2 stalling indices under both 
resting and TCR-activated status.21 Integrating these criteria, we 
Figure 6 Transcriptional interference configurations created through proviral insertion. Retroviral integration amidst known transcriptional 
start sites generates de novo promoter configurations leading to transcriptional interference. For each VIS, CTSS contained within ±1 kb flank-
ing regions are described by their relative orientation to VIS as divergent, convergent, upstream tandem, or downstream tandem. (a) Schematic 
 representation of promoter arrangements between provirus and CTSS. In CTSS-dense regions, multiple CTSS:VIS orientation pairings are possible. 
(b) Each  VIS-flanking region is further grouped according to its total unique configuration multiplexity and plotted against total CTSS per VIS-flanking 
region. (c) Distribution plot of Stalling Index observed at 6,210 CTSS within 1,210 VIS-flanking regions in either “Resting” or “Activated TCR” states. 
Each VIS-flanking region is categorized by their relative Stalling Index change concordant with TCR (T-cell receptor) activation as: “activated,” “still 
stalled,” “arrested,” “low activity.” Threshold for stalling set at 5 per Zeitlinger et al.26 CTSS, CAGE tag clusters; VIS, vector integration sites.
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categorized CTSS near VIS by their relative RNPII enrichment 
ratio change upon TCR activation (Resting to Activated) with a 
threshold set at 5. Stalled promoters with indices falling below 
threshold were defined as “activated.” Conversely promoters 
whose index change surpassing threshold were termed “arrested,” 
while promoters with ratios not crossing the threshold were de-
fined as “still stalled” (above 5) or “low activity” (below 5). In total 
we found 6,210 CTSS with significant RNPII enrichment within 
1 kb distance of 1,210 VIS (a slight decrease from 1,553 VIS in 
Figure 6c). Of the 6,210 CTSS, 3,811 (61.3%) were released from 
their stalled states upon TCR activation, 2,067 (33.3%) remained 
stalled while very few CTSS (8) (<0.1%) had stalling ratio increase 
above threshold upon TCR activation, and 324 (5.2%) had low 
activity (Figure 6c).
DISCUSSION
High-definition mapping of VIS from four patients infused with 
iC9-T cells after haplo-HSCT allowed us to assess the in vivo 
clonal dynamics of VIS in iC9-T cells that expanded exponen-
tially during clinical manifestations of GvHD and contracted after 
administration of the apoptosis-inducing CID. We found that VIS 
are preferentially located near promoter/enhancer regions and are 
efficiently eliminated without bias of selection when the iC9 safety 
switch is activated by CID. With respect to long-term persisting 
iC9-T cells not eliminated by CID, we hypothesize that both low 
transcription activity and local genome context flanking VIS may 
contribute to reducing proviral transgene expression in vivo.
Mapping of VIS with respect to genomic elements in geneti-
cally modified T lymphocytes has been used previously to assess 
the safety of GRV.11,13,27 The strength of our analysis relies on the 
extensive characterization of VIS using recently available epi-
genetic and promoter-level atlases to query biological questions 
underpinning not only the safety of GRV transduction in T lym-
phocytes, but also the in vivo efficacy of the inserted suicide gene.
The safety of GRV is highly dependent on their genomic inser-
tion, as is clearly documented by the insertional mutagenesis in 
hematopoietic stem cells.28 To characterize VIS in T lymphocytes, 
we considered several facets of host transcriptional regulation 
including: chromatin accessibility, CpG methylation profile, chro-
matin mark patterning, RNPII enrichment, gene expression, and 
TSS. Making use of bioinformatics tools such as ChromHMM 
and GREAT,15,16 and also previous GRV11,13 and lentiviral inser-
tion data sets,14 we determined that VIS from GRV are biased for 
promoter/enhancer-associated states, whereas lentiviral integra-
tions target actively transcribed regions. Moreover, gene ontology 
enrichment analysis of GRV integration in cis-regulatory regions 
of genes reveal significant association with T-cell–related func-
tions, which is in agreement with GRV integration preference for 
transcriptionally active regions at time of transduction ex vivo.13 
Nevertheless, despite integrating near active gene promoters,11 
no oncogenic T-cell transformation has been reported in clinical 
trials using human T cells genetically modified with GRV so far, 
underlining the safety of these viruses in T lymphocytes.
To assess the efficacy of the inserted suicide gene in T lym-
phocytes, we summarized VIS clonal dynamics into four distinct 
profiles (Sensitive/Eliminated, Insensitive/Short-term, Sensitive/
Persisted, and Insensitive/Persisted) according to their response 
to CID and normalized VIS copy number (NVC) over time. It 
is important to note that transduction of T lymphocytes ex vivo 
results in a range of VIS multiplicity per transduced clone, with 
the cumulative iC9 expression tuned by transcriptional output per 
transgene copy. Thus, genetically identical progeny cells from a 
single transduced T-cell lineage will have different levels of trans-
gene expression depending on their individual phenotypic status 
and external factors. While it is impossible to clonally segregate 
VIS by sequencing bulk T lymphocytes, we proposed a degree 
of stratification for VIS clonal populations by examining their 
copy number fluctuation over time. We reasoned that alloreac-
tive iC9-T cell lineages causing GvHD are more proliferative than 
nonalloreactive cells, which means they have greater progeny 
numbers and corresponding VIS copy numbers. We found that 
the majority (roughly 75–87%) of VIS with high NVC at time of 
GvHD onset were eliminated by CID administration (Sensitive/
Eliminated), while the remaining VIS detectable long-term 
post-CID were generally characterized by low NVC (Sensitive/
Persisted and Insensitive/Persisted). Among the four patients we 
studied, VIS of Pt. 1 seem to be an exception to this categorization. 
Of note, iC9-T cells of Pt. 1 contained the highest proportion of 
CD4+ T cells at the time of GvHD occurrence compared to the 
other three patients.2,3 Whether the predominance of CD4+ T cells 
alters the predicted clonal dynamics of VIS remains to be investi-
gated. However, Pt. 1 clinically responded to the administration of 
CID with resolution of GvHD as observed in the other patients.2,3
We propose two possible explanations for the existence of 
VIS and corresponding iC9-T cells not eliminated by CID. The 
first is that these cells are in a quiescent state in vivo with little 
or no transcriptional activity and have insufficient expression of 
iC9 to trigger apoptosis. This description fits with the in vitro data 
showing that within the iC9-T cell bulk cells, we can identify cells 
with low transcriptional activity in the absence of TCR stimula-
tion (Supplementary Figure S4), and the evidence that iC9-T 
cells spared by CID fall in the VIS category of low NVC at time 
of GvHD onset. This explanation is also consistent with the previ-
ous observation that quiescent T lymphocytes transduced with a 
GRV encoding a TCR show transgene downregulation in vivo.29 
The second possibility is that heterogeneous CID susceptibility 
in iC9-T lineages harboring multiple VIS is due to cell-extrinsic 
stimuli manifesting at the genome level to modulate transcrip-
tional output of individual transgene unit.
De novo DNA methylation of the virus LTRs is a  well-recognized 
mechanism downregulating transgene expression in hematopoi-
etic stem cells.30 However, recent evidence precludes CpG methyla-
tion of GRV LTRs as a distinct suppressive mechanism for proviral 
transgene expression in T lymphocytes in vivo.29 Our analysis 
surveying DNA regions flanking the VIS indicates VIS preference 
for regions of low CpG density but high methylation, which differ 
from TSS-proximal sequences that are CpG-rich and low methyla-
tion (Figure 4 and Supplementary Figure S5). Therefore, we con-
cluded that CpG methylation of  VIS-flanking sequences is unlikely 
to function as a de novo repressive mechanism for proviral LTR in 
T lymphocytes. In contrast, the immediate consequence of GRV 
integration near active promoter regions is the formation of de 
novo promoter arrangements, from which we identified plausible 
TI mechanisms affecting nearly 50% of all VIS. We described TI 
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in terms of both promoter configuration and RNPII regulation31 
to illustrate the intricate trafficking required to ensure availabil-
ity of preinitiation complexes to proviral LTR (Supplementary 
Figure S6—“Stalled RNPII interference”). We noted >95% of all 
host promoter-associated RNPII are in fact stalled, leading to 
demonstrable TI effects.32,33 Furthermore, 60% of these promoters 
are fully released upon TCR activation and 35% have decreased 
stalling indices. Since external stimuli are involved in determin-
ing the functional status of iC9-T cells in vivo, it is plausible that a 
dynamic process such as TCR stimulation rather than static repres-
sion mechanisms, such as epigenetic marks, affects gene promoters 
proximal to VIS promoting their transition from transcriptionally 
paused promoters to released promoters (Supplementary Figure 
S7). TCR stimulation may thus indirectly modulate iC9 expression 
by alleviating transcriptional repression from nearby host promot-
ers and promote iC9 mRNA expression as demonstrated by the 
experiment performed in vitro (Supplementary Figure S4).
In conclusion, we demonstrate here clonal dynamics of T lym-
phocytes engineered with the iC9 safety switch can be followed 
by longitudinal VIS mapping, and that based on bioinformatics 
analysis, there is no selection bias for either the in vivo expan-
sion or CID-mediated elimination of iC9-T cells. We propose that 
CID-mediated elimination of iC9-T cells is determined by a mini-
mum expression threshold for iC9 transgene, which is dependent 
on TCR activation state of the iC9-T cells, as well as cis-acting 
influences by host promoters on the proviral transgene.
MATERIALS AND METHODS
Patients and study design. The CASPALLO trial IND 13813 was previously 
described.2,3 It was designed to assess the safety and efficacy of escalating 
doses of donor-derived T cells genetically modified with a GRV (gammaret-
roviral vector) to express the iC9 and ΔCD19 transgenes in patients under-
going haplo-HSCT.2,34 Patients who developed acute GvHD grade I or II after 
infusion of iC9-T cells received 0.4 mg/kg of the CID (AP1903/Rimiducid, 
Bellicum Pharmaceuticals, Houston, TX).2 We set out to analyze total VIS 
diversity over time in four patients who developed GvHD after the infusion 
of iC9-T cells and were treated with CID to delete alloreactive iC9-T cells.2,3 
Table 1 summarizes the characteristics of the analyzed samples. The clinical 
study was approved by the institutional review board of Baylor College of 
Medicine and the FDA and reviewed by the Recombinant DNA Advisory 
Committee.
Amplification and sequencing of VIS. Genomic DNA was isolated from fro-
zen peripheral blood mononuclear cells using the Qiagen DNA extraction 
kit according to manufacturer instructions, then whole genome amplified 
by REPLI-G Mini kit (Qiagen, Hilden, Germany). For targeted amplifi-
cation of retroviral integration sites, we used fusion primers and nested 
integrated PCR, in a modification of the previously published flanking-
sequence exponential anchored PCR.35 Additional methodologies describ-
ing the mapping and analysis of the VIS are provided in Supplementary 
Materials and Methods and Supplementary Figure S8. Data analysis and 
graphing were done using the R packages data tables, dplyr and ggplot2. 
SUPPLEMENTARY MATERIAL
Figure S1. Functional annotation and gene ontology enrichment of 
lentiviral integration sites.
Figure S2. Calculated copy numbers of unique VIS.
Figure S3. Venn diagram and GRV VIS breakdown by patient, CID 
profile and collection time.
Figure S4. Detection of iC9 copy numbers at mRNA and DNA levels 
in iC9-T cells ex vivo.
Figure S5. CpG methylation profile for TSS flanking regions.
Figure S6. Model for transcriptional interference due to Pol II  pausing 
on host promoters near VIS.
Figure S7. Model for predicted transgene expression among 
all iC9-T cells harboring multiple proviral iC9 transgene integrations.
Figure S8. Flow chart of the methodology.
Materials and Methods
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